SPIA
INKT icon

Steward Partners Investment Advisory’s MiNK Therapeutics INKT Stock Holding History

Steward Partners Investment Advisory’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Buy
+2,000
New +$22.3K ﹤0.01% 3206

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Steward Partners Investment Advisory's INKT Position: Q1 2026 in Review

Steward Partners Investment Advisory opened a new position in MiNK Therapeutics (INKT) in Q1 2026: 2,000 shares worth $21.1K. The stake represents ﹤0.01% of the portfolio and ranks #3206 among its holdings.

23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Steward Partners Investment Advisory held 2,000 shares of MiNK Therapeutics worth $21.1K as of Q1 2026.
  • MiNK Therapeutics was a new Steward Partners Investment Advisory position in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3206 holding.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.